September 12, 2026

Firdapse (Amifampridine): The 2035 Generic Opportunity Window

Firdapse generated $358.4 million in 2025 sales, up 17.1% year over year. No generic is FDA-approved or sold in the US today; settlements with Lupin, Hetero, Inventia, and Teva keep it that way until at least 2035.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.